Boston Scientific Buys Cameron Health For First Subcutaneous ICD
This article was originally published in The Gray Sheet
Deal includes $150 million up front, but is worth up to $1.35 billion with potential milestone payments.
You may also be interested in...
Data from the 985-patient EFFORTLESS registry was presented at this year's Heart Rhythm Society annual meeting, lending support for Boston Scientific's subcutaneous ICD system, according to study investigators. The company envisions a future, "modular" approach to cardiac rhythm management.
Boston's Emblem S-ICD upgrade was approved by FDA and in Europe earlier than anticipated.
The cuts expand on a 2011 restructuring plan, with hopes of reducing operating expenses by up to $375 million at the end of 2013.